Latest news and press releases about BioRestorative Therapies, Inc. (BRTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100.
Price
| Price | $2.55 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.76 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -423.84% |
| Return on Invested Capital | -464.86% |
| Return on Assets | -238.27% |
| Gross Margin | 92.09% |
| Operating Margin | -3975.00% |
| Net Margin | -3089.55% |
Related companies: BOLT · COCP · DWTX · EDSA · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of BRTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks